drugset
Drugs / TOMARALIMAB
last change Jan 2019 re-read 3 minutes ago

TOMARALIMAB

also known as OPN-305

Monoclonal antibody targets TLR2 via inhibition

Developed for
myelodysplastic syndrome
Investigated by
Opsona Therapeutics Ltd. · H. Lee Moffitt Cancer Center and Research Institute · M.D. Anderson Cancer Center · Montefiore Medical Center · New York Presbyterian Hospital

Trials 3

today NCT03337451 · Ph 1/2 NCT02363491 · Ph 1/2 NCT01794663 · Ph 2
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT03337451 Feb 2018 → Jan 2019 myelodysplastic syndrome Opsona Therapeutics Ltd. Completed No outcome recorded
Phase 1/2 NCT02363491 Jan 2015 → Dec 2018 myelodysplastic syndrome Opsona Therapeutics Ltd. Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01794663 Oct 2012 → Jun 2016 — Opsona Therapeutics Ltd. Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as TOMARALIMAB ChEMBL registry synonym — accepted as the source's own label CHEMBL4298067 ↗
Known as OPN-305 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03337451 ↗
2

NCT02363491 ↗

NCT01794663 ↗
Action Inhibit “Toll-like receptor 2 antagonist” CHEMBL4298067 ↗
1

“blocks Toll-like Receptor 2” NCT01794663 ↗
Modality Monoclonal antibody “OPN-305 is a monoclonal antibody that blocks Toll-like Receptor 2” NCT01794663 ↗
Route Intravenous “Intravenous infusion for 1 hour at start of transplant procedure” NCT01794663 ↗
Target TLR2 “Toll-like receptor 2 antagonist” CHEMBL4298067 ↗